Treatment Strategy to Enhance Nrf2 Signaling in Older Adults

NCT ID: NCT04848792

Last Updated: 2025-08-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-09

Study Completion Date

2025-05-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Exercise is the cornerstone of disease prevention and often an important component of treatment. However, the efficacy of an exercise stimulus is reduced with aging. This study will investigate whether adding a treatment with phytonutrients found in cruciferous vegetables can improve the exercise response in older individuals.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Redox balance plays a key role in the age-associated increased risk for diseases. One reason for the lower resistance to oxidative stress with age is a gradual shift in the redox state toward a more oxidized cellular environment resulting in disruption of cell signaling. Nuclear erythroid factor 2-related factor 2 (Nrf2) is the master regulator of antioxidant defenses. Nrf2 drives expression of a host of genes involved in cytoprotection and antioxidant defenses. The Traustadottir lab was the first to demonstrate Nrf2 activation in response to acute exercise in humans, and in agreement with animal data, found an age-related impairment in exercise-induced Nrf2 signaling. This underscores an important problem related to aging, namely that older individuals are less sensitive to an exercise stimulus compared to younger cohorts. The focus of the proposed study is to try to solve this problem by amplifying the signal and mitigating the "exercise desensitization" exhibited by older individuals to restore redox balance. This study will test the hypothesis that combining acute exercise with sulforaphane will improve Nrf2 activation and downstream signaling in older adults compared to either alone. Sulforaphane (SFN) is a phytonutrient found in high concentrations in cruciferous vegetables and a potent Nrf2 activator. The hypothesis will be tested using two different approaches; the first experiment will use an in vivo-ex vivo approach, where peripheral blood mononuclear cells (PBMCs) collected from older men and women (≥60y, n=30) pre- and post-acute exercise (in vivo) will be cultured and stimulated with SFN (ex vivo). This allows for a greater experimental control of the SFN stimulus. The second experiment will test the clinical translation applying the sulforaphane stimulus in vivo through an oral supplementation of sulforaphane in the form of whole broccoli sprout material, prior to acute exercise, in the same individuals. This second experiment will be a randomized placebo-controlled cross-over design. For all trials Nrf2 signaling will be measured by Nrf2 activation through an ARE binding assay, nuclear to whole cell ratio of Nrf2 protein, and Nrf2-dependent gene expression (HO-1, GCLC, NQO1, GR). Potential sex differences will be investigated. The insights gained from this study are whether combining simple interventions in the category of healthy lifestyle and preventive medicine can improve the adaptive response to exercise in older individuals. This could have an enormous impact by improving the health and well-being of older Americans.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging Problems

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Humans
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Investigators
The design of this experiment will be a randomized, double-blind, placebo-controlled, cross-over design, where each subject will serve as their own control. Randomization of order of trials (supplement/placebo) will be performed by a person that is otherwise not part of study personnel, and study personnel and subjects will be blinded to the order. The person doing the randomizing will keep a record of the order using study ID, and researchers will be unblinded upon completion of data collection.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SFN supplement

The oral sulforaphane supplement is a myrosinase-active whole broccoli sprout material (EnduraCell Bioactive, Cell-Logic, Queensland, AU) containing 14 mg SFN per capsule. Three capsules will be consumed 90 min prior to the start of the acute exercise trial. The dose of 3 capsules is equivalent to approximately 220 µmol of SFN, which is comparable to that of other studies using broccoli sprout extracts and the recommended single dose.

Group Type EXPERIMENTAL

Sulforaphane

Intervention Type DIETARY_SUPPLEMENT

Myrosinase-active whole broccoli sprout material

Placebo capsules

Intervention Type DIETARY_SUPPLEMENT

Placebo capsules

Placebo

Placebo capsules provided by Cell-Logic.

Group Type PLACEBO_COMPARATOR

Sulforaphane

Intervention Type DIETARY_SUPPLEMENT

Myrosinase-active whole broccoli sprout material

Placebo capsules

Intervention Type DIETARY_SUPPLEMENT

Placebo capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sulforaphane

Myrosinase-active whole broccoli sprout material

Intervention Type DIETARY_SUPPLEMENT

Placebo capsules

Placebo capsules

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

EnduraCell Bioactive

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women, 60 years and older
* Competent to independently give informed consent
* Successful completion of screening
* Maximal oxygen consumption below the 60th percentile based on gender:
* Women: ≤ 21.2 mL/kg/min
* Men: ≤ 30.5 mL/kg/min

Exclusion Criteria

* Estrogen supplementation (in any form) within the previous 6 months
* Any medication that could affect outcome measures such as statins, blood pressure medications, or anti-depressives
* Use of anti-oxidant supplements, in excess of standard multi-vitamins (1 tablet/day) and/or any supplements known to target Nrf2 including resveratrol, Protandim, and sulforaphane
* Current smoker
* Body Mass Index (BMI) greater than 33 kg/m2 (Class I Obesity)
* Any chronic illness that could affect outcome measures, including diabetes, liver or renal disease, or cancer (other than skin cancer)
* History of a myocardial infarction within the last 6 months, clinically significant aortic stenosis, use of cardiac defibrillator, or uncontrolled angina
* Clinically significant arrhythmia on a resting EKG or significant EKG changes during the baseline VO2 max test
* Any other condition that would contraindicate maximal exercise testing, including elevated blood pressure at rest (systolic BP \>150 or diastolic BP \>90 mm Hg on at least 2 measurements, at least 10 minutes apart) or musculoskeletal problems
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Villanova University

OTHER

Sponsor Role collaborator

Northern Arizona University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Northern Arizona University

Flagstaff, Arizona, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Rodriguez DJ, Ostrom EL, Chassman C, Robertson J, Pan V, Buscaglia R, Eggler AL, Traustadottir T. Sulforaphane improves exercise-induced NRF2 signaling in older adults: an in vivo-ex vivo approach. Geroscience. 2025 Oct 16. doi: 10.1007/s11357-025-01939-5. Online ahead of print.

Reference Type DERIVED
PMID: 41099966 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1551363

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

NR Supplementation and Exercise
NCT04907110 COMPLETED NA
Researching Economical Adjuvants to Cancer Therapy
NCT07305259 RECRUITING EARLY_PHASE1